Asplenia
6
4
4
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
17%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (6)
Development of an Italian Questionnaire for Splenectomized Patients Using a Delphi Consensus Method
Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients
Evaluation of the Effectiveness of an Educational Intervention in Splenectomized Patients
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients
B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals